Just 9% of patient groups rate pharma industry positively in terms of fair pricing policies, according to report

About The Authors

15th May 2019 13:01 - Pharmaceutical

Just 9% of patient groups rate pharma industry positively in terms of fair pricing policies: An annual report based on findings of a PatientView corporate reputation survey found that less than one in ten patient groups rated pharma companies as ‘excellent’ or ‘good’ when it came to pricing of drugs.

The annual poll now in its 8th year asked 1,500 patient groups from 78 countries covering 102 medical specialities to reveal their views on the corporate reputation of the pharma industry during 2018. It analysed the industry as a whole as well as 46 individual companies, with respondents giving feedback in 12 performance areas including how well companies provide high-quality patient information, how transparent they are about pricing and whether they provide more services than just medicines.

The 2018 survey

The results showed that patient group attitudes towards the pharma industry have changed little since the previous survey in 2017, with 41% of respondents saying they felt the industry as a whole had an 'excellent' or 'good' corporate reputation, slightly down on 2017 when 43% said the same.

When it came to products, 53% said they believed the pharma industry was ''excellent' or 'good' at bringing high-quality goods to market, down four percentage points since 2017 when the figure stood at 57%.

The percentage of respondents saying they believed the pricing of drugs was 'excellent' or 'good' was much lower, with just 9% rating the industry positively in this area.

Pharma companies top five

Looking at the individual performance of pharma companies in terms of overall corporate reputation, ViiV Healthcare came out top as it did in 2017, followed by Gilead in second place up a place from 2017 when it was in third position. Janssen was ranked third, up two places from 2017 when it was in fifth position.

In fourth place was Novartis, a non-mover since 2017 and in fifth, AbbVie down from second place in 2017.

In terms of the largest position change for overall reputation, Takeda moved up 30 places from 2017, from 37th to 7th in 2018.  Sanofi was also a mover, edging up five places to tenth position in the 2018 poll.

Alex Wyke, PatientView CEO said:

“Only 30% out of the whole sample were even willing to nominate a company that they thought were good or best at transparency and pricing, even though nearly every group has relationships with pharma companies.”



Sign up for free insights from your sector…

Antispam code: 7499

Support Us..

We hope that you have found this article useful. This section is freely available for all to use. Please help support it by liking us or following us on our social media platforms:

Share this article..


For updated Pharmaceutical insights please follow us on @DJS_Pharma or use our RSS feed

Other Pharmaceutical Research Findings

Other Latest Market Research Insights

© DJS Research 2019